Clorox Earnings Reports

Clorox's Q2 2025 net sales decreased by 15% to $1.69 billion, while diluted EPS increased by 105% to $1.54 and adjusted EPS decreased by 28% to $1.55. The company has updated its fiscal year 2025 outlook, expecting net sales to be down 1% to up 2% and adjusted EPS to be between $6.95 and $7.35.

Clorox reported a 27% increase in net sales to $1.76 billion, driven by higher volume due to lapping the cyberattack. Diluted EPS increased by 371% to $0.80, and adjusted EPS increased by 280% to $1.86. The company has raised its gross margin and EPS outlook for the year.

Clorox reported a decrease in net sales by 6% to $1.9 billion, driven by the Argentina divestiture, unfavorable price mix, and lower volume. However, gross margin increased by 380 basis points to 46.5%. Diluted EPS increased by 22% to $1.73, and adjusted EPS increased by 9% to $1.82.

Clorox reported a 5% decrease in net sales to $1.81 billion, impacted by lower volume from cyberattack-related distribution losses and unfavorable foreign exchange rates. However, adjusted EPS increased by 13% to $1.71, driven by pricing and cost savings. The company is on track to restore lost distribution by the end of Q4 and expects to exit fiscal year 2024 with strong fundamentals.

Clorox reported a 16% increase in net sales to $1.99 billion, driven by higher volume as the company rebuilt customer inventories following the August cyberattack and favorable price mix. Gross margin increased by 730 basis points to 43.5%. Diluted EPS decreased by 6% to $0.75, while adjusted EPS increased by 120% to $2.16.

Clorox reported a decrease in net sales by 20% to $1.4 billion, primarily due to lower volume resulting from a cyberattack. Diluted EPS decreased by 75% to 17 cents, including investments in digital capabilities and cyberattack expenses. Adjusted EPS decreased by 47% to 49 cents.

Clorox reported a 12% increase in net sales to $2.0 billion, driven by favorable price mix. Diluted EPS increased by 75% to $1.42, and adjusted EPS increased by 80% to $1.67. The company delivered double-digit organic net sales growth in all reportable segments and achieved sequential quarterly improvement in gross margin.

Clorox reported a 6% increase in net sales to $1.91 billion, driven by favorable price mix and an 8% increase in organic sales. The gross margin increased by 590 basis points to 41.8%. However, diluted EPS decreased to a loss of $1.71, impacted by a noncash impairment charge. Adjusted EPS increased by 15% to $1.51.

Clorox's Q2 2023 results showed a 1% increase in net sales to $1.72 billion, driven by favorable price mix, with organic sales up 4%. Gross margin improved to 36.2%. Diluted EPS increased 43% to $0.80, and adjusted EPS increased 48% to $0.98. The company is updating its fiscal year 2023 outlook, expecting net sales to be between a 2% decrease to a 1% increase and adjusted EPS to be between $4.05 and $4.30.

Clorox's Q1 2023 net sales decreased by 4% to $1.74 billion, with organic sales down 2%. Diluted EPS decreased by 40% to 68 cents, while adjusted EPS decreased by 23% to 93 cents. The company is maintaining its fiscal year 2023 outlook.

Clorox reported flat net sales of $1.8 billion for Q4 2022, with organic sales up 1%. Diluted EPS increased by 4% to $0.81, while adjusted EPS decreased by 2% to $0.93. The company announced a streamlined operating model expected to generate $75 million to $100 million in annual savings.

Clorox reported Q3 fiscal year 2022 results with a net sales increase of 2% to $1.8 billion. Diluted EPS increased significantly due to a noncash impairment in the Vitamins, Minerals and Supplements business during the year-ago period, while adjusted EPS decreased due to lower gross margin. The company updated its outlook to reflect higher than previously anticipated commodity and manufacturing and logistics costs.

Clorox reported a decline in net sales by 8% to $1.7 billion, driven by a 10-point decline in volume, though favorable price mix contributed 2 points. Gross margin decreased significantly by 1240 basis points to 33%. Diluted EPS decreased by 72% to $0.56, and adjusted EPS declined by 67% to $0.66.

Clorox reported a 6% decrease in net sales to $1.8 billion and a 65% decrease in diluted EPS to $1.14. The company is managing inflationary pressures through pricing actions and cost reduction initiatives and is on track to meet its fiscal 2022 outlook.

Clorox reported a decrease in sales and diluted net earnings per share for the fourth quarter. Sales were down 9%, and diluted EPS decreased by 68%. The company faced challenges including decelerating shipments from peak pandemic levels, unfavorable price mix, and increased costs.

Clorox reported flat sales in Q3 2021 compared to the previous year, with a diluted net loss per share of $0.49. Adjusted EPS was $1.62, a 14% decrease year-over-year. The company is on track to deliver its best full-year top-line growth in more than 20 years.

Clorox reported a 27% increase in sales and a 39% increase in diluted earnings per share for the second quarter of fiscal year 2021. Organic sales grew by 26%.

Clorox reported a strong start to fiscal year 2021 with a 27% increase in sales and a 103% increase in diluted EPS for the first quarter, driven by broad-based strength across its portfolio and double-digit sales growth in all reportable segments.

Clorox reported strong Q4 2020 results with a 22% sales increase and a 28% increase in diluted EPS. The growth was driven by strong demand for their products due to COVID-19 and consumers spending more time at home.

Clorox reported a 15% increase in sales and a 31% increase in diluted earnings per share for Q3 2020. The company experienced sales and earnings growth across all reportable segments, driven by strong demand for disinfecting products and broad-based growth across its portfolio.

Clorox's Q2 2020 results showed a sales decrease of 2% but a diluted EPS increase of 4%. The company is confident in returning to growth in the back half of the fiscal year with investments in innovation.